These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24821657)

  • 21. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
    Hammwöhner M; Goette A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral anticoagulants for Asian patients with atrial fibrillation.
    Sabir I; Khavandi K; Brownrigg J; Camm AJ
    Nat Rev Cardiol; 2014 May; 11(5):290-303. PubMed ID: 24614113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AParadigm Shift: The New Novel Oral Anticoagulation Agents.
    Saeed W; Burke JF; Mirrani G; Sirinivasa M; Nabi U; Hayat U; Khan Z; Sardar MR
    J Coll Physicians Surg Pak; 2016 Jul; 26(7):611-9. PubMed ID: 27504556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anticoagulation for patients with non-valvular atrial fibrillation].
    Mizoguchi T; Yasaka M
    Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations.
    Deftereos S; Tsounis D; Giannopoulos G; Kossyvakis C; Panagopoulou V; Raisakis K; Stefanadis C
    Curr Clin Pharmacol; 2012 Aug; 7(3):166-74. PubMed ID: 22564122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation Therapy and NOACs in Heart Failure.
    Thomas I; EncisoSilva J; Schlueter M; Greenberg B
    Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)].
    Ieko M
    Rinsho Byori; 2014 Oct; 62(10):948-57. PubMed ID: 27526540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
    Türk UÖ; Acar RD; Akgün T; Emren V; Kanat S; Karacağlar E; Kepez A; Kul Ş; Özel E; Şimşek E; Yakar Tülüce S; Tülüce K; Camm AJ
    Turk Kardiyol Dern Ars; 2020 Apr; 48(3):289-303. PubMed ID: 32281950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants.
    Kasmeridis C; Apostolakis S; Ehlers L; Rasmussen LH; Boriani G; Lip GY
    Pharmacoeconomics; 2013 Nov; 31(11):971-80. PubMed ID: 24085625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.